Edwards Lifesciences Corp
EW81.195USD
-0.295-0.36%
시장 운영 시간 （ET）시세는 15분 지연됩니다
47.15B시가총액
34.58P/E TTM
자세한 내용은 Edwards Lifesciences Corp 회사
Edwards Lifesciences Corporation is the global structural heart company. The Company partners with clinicians and researchers and invests in research and development to improve care for those impacted by structural heart disease. Its product categories include Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), and Surgical Structural Heart. It provides transcatheter heart valve replacement technologies designed for the minimally-invasive replacement of aortic heart valves. TAVR category includes the Edwards SAPIEN 3, the Edwards SAPIEN 3 Ultra and the Edwards SAPIEN 3 Ultra RESILIA systems. TMTT category includes the PASCAL Precision transcatheter repair system, EVOQUE tricuspid valve replacement system and Cardioband tricuspid valve reconstruction system. Its INSPIRIS RESILIA aortic valve, offers RESILIA tissue and VFit technology. It is managed in various geographical regions, such as United States, Europe, Japan and Rest of World.
Edwards Lifesciences Corp 정보
종목 코드 EW
회사 이름Edwards Lifesciences Corp
상장일Mar 27, 2000
CEOZovighian (Bernard J)
직원 수15800
유형Ordinary Share
회계 연도 종료Mar 27
주소One Edwards Way
도시IRVINE
증권 거래소NASDAQ OMX NASDAQ Basic NYSE
국가United States of America
우편 번호92614
전화19492502500
웹사이트https://www.edwards.com
종목 코드 EW
상장일Mar 27, 2000
CEOZovighian (Bernard J)
Edwards Lifesciences Corp의 회사 임원진
이름
이름/직위
직위
주식 보유
변동
Mr. Scott B. Ullem
Mr. Scott B. Ullem
Chief Financial Officer, Corporate Vice President
Chief Financial Officer, Corporate Vice President
282.82K
--
Mr. Steven R. (Steve) Loranger
Mr. Steven R. (Steve) Loranger
Independent Director
Independent Director
76.00K
+4682.00%
Mr. Bernard J. Zovighian
Mr. Bernard J. Zovighian
Chief Executive Officer, Director
Chief Executive Officer, Director
39.57K
--
Mr. Daniel J. Lippis
Mr. Daniel J. Lippis
Corporate Vice President - Transcatheter Aortic Valve Replacement
Corporate Vice President - Transcatheter Aortic Valve Replacement
21.26K
--
Mr. Daveen Chopra
Mr. Daveen Chopra
Corporate Vice President - Transcatheter Mitral and Tricuspid Therapies
Corporate Vice President - Transcatheter Mitral and Tricuspid Therapies
17.91K
-2000.00%
Dr. David T. Feinberg, M.D.
Dr. David T. Feinberg, M.D.
Independent Director
Independent Director
5.84K
+3528.00%
Mr. Donald E. Bobo, Jr.
Mr. Donald E. Bobo, Jr.
Corporate Vice President - Strategy and Corporate Development
Corporate Vice President - Strategy and Corporate Development
--
--
Mr. Nicholas J. (Nick) Valeriani
Mr. Nicholas J. (Nick) Valeriani
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Kieran T. Gallahue
Mr. Kieran T. Gallahue
Independent Director
Independent Director
--
--
Ms. Leslie S. Heisz
Ms. Leslie S. Heisz
Independent Director
Independent Director
--
--
더 보기
이름
이름/직위
직위
주식 보유
변동
Mr. Scott B. Ullem
Mr. Scott B. Ullem
Chief Financial Officer, Corporate Vice President
Chief Financial Officer, Corporate Vice President
282.82K
--
Mr. Steven R. (Steve) Loranger
Mr. Steven R. (Steve) Loranger
Independent Director
Independent Director
76.00K
+4682.00%
Mr. Bernard J. Zovighian
Mr. Bernard J. Zovighian
Chief Executive Officer, Director
Chief Executive Officer, Director
39.57K
--
Mr. Daniel J. Lippis
Mr. Daniel J. Lippis
Corporate Vice President - Transcatheter Aortic Valve Replacement
Corporate Vice President - Transcatheter Aortic Valve Replacement
21.26K
--
Mr. Daveen Chopra
Mr. Daveen Chopra
Corporate Vice President - Transcatheter Mitral and Tricuspid Therapies
Corporate Vice President - Transcatheter Mitral and Tricuspid Therapies
17.91K
-2000.00%
Dr. David T. Feinberg, M.D.
Dr. David T. Feinberg, M.D.
Independent Director
Independent Director
5.84K
+3528.00%
수익 분석
통화: USD마지막 업데이트: Tue, Jan 6
통화: USD마지막 업데이트: Tue, Jan 6
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
FY2017
FY2016
FY2015
사업별USD
이름
수익
비율
Transcatheter Aortic Valve Replacement
1.15B
74.04%
Surgical Heart Valve Therapy
258.00M
16.61%
Transcatheter Mitral and Tricuspid Therapies
145.20M
9.35%
지역별USD
이름
수익
비율
United States
907.50M
58.43%
Europe
387.90M
24.98%
Rest of the world
167.60M
10.79%
Japan
90.10M
5.80%
사업별
지역별
사업별USD
이름
수익
비율
Transcatheter Aortic Valve Replacement
1.15B
74.04%
Surgical Heart Valve Therapy
258.00M
16.61%
Transcatheter Mitral and Tricuspid Therapies
145.20M
9.35%
주식 보유 통계
마지막 업데이트: Sat, Jan 10
마지막 업데이트: Sat, Jan 10
주주
주주 유형
주주
주주
비율
The Vanguard Group, Inc.
12.03%
BlackRock Institutional Trust Company, N.A.
5.26%
State Street Investment Management (US)
4.41%
Wellington Management Company, LLP
3.59%
JP Morgan Asset Management
3.09%
기타
71.62%
주주
주주
비율
The Vanguard Group, Inc.
12.03%
BlackRock Institutional Trust Company, N.A.
5.26%
State Street Investment Management (US)
4.41%
Wellington Management Company, LLP
3.59%
JP Morgan Asset Management
3.09%
기타
71.62%
주주 유형
주주
비율
Investment Advisor
46.83%
Investment Advisor/Hedge Fund
30.96%
Hedge Fund
3.47%
Pension Fund
2.27%
Research Firm
2.17%
Bank and Trust
1.96%
Sovereign Wealth Fund
1.37%
Individual Investor
0.93%
Endowment Fund
0.83%
기타
9.21%
기관 주식 보유
마지막 업데이트: Mon, Dec 8
마지막 업데이트: Mon, Dec 8
보고 기간
기관 수
보유 주식
비율
변동
2025Q4
2452
517.66M
93.53%
--
2025Q3
2537
517.80M
94.00%
-1.50M
2025Q2
2614
519.17M
94.35%
-5.19M
2025Q1
2599
525.51M
93.66%
-25.15M
2024Q4
2585
522.16M
89.45%
+17.15M
2024Q3
2546
504.88M
87.53%
-10.03M
2024Q2
2541
515.71M
87.77%
+1.93M
2024Q1
2555
513.21M
86.74%
-8.92M
2023Q4
2556
503.19M
87.55%
-12.35M
2023Q3
2509
516.79M
88.03%
-521.37K
더 보기
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
The Vanguard Group, Inc.
70.09M
12.08%
+359.01K
+0.51%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
30.52M
5.26%
-370.16K
-1.20%
Sep 30, 2025
State Street Investment Management (US)
25.62M
4.41%
-14.75K
-0.06%
Sep 30, 2025
Wellington Management Company, LLP
20.80M
3.59%
+977.93K
+4.93%
Sep 30, 2025
JP Morgan Asset Management
17.92M
3.09%
-2.17M
-10.80%
Sep 30, 2025
Jennison Associates LLC
13.96M
2.41%
+2.29M
+19.60%
Sep 30, 2025
Fidelity Management & Research Company LLC
13.03M
2.25%
+10.73M
+466.56%
Sep 30, 2025
Geode Capital Management, L.L.C.
12.84M
2.21%
+114.73K
+0.90%
Sep 30, 2025
Walter Scott & Partners Ltd.
9.96M
1.72%
+1.05M
+11.73%
Sep 30, 2025
Union Investment Privatfonds GmbH
8.60M
1.48%
+19.17K
+0.22%
Sep 30, 2025
더 보기
관련 ETF
마지막 업데이트: Sat, Dec 6
마지막 업데이트: Sat, Dec 6
이름
비율
iShares U.S. Medical Devices ETF
4.72%
Future Fund Long/Short ETF
3.86%
iShares Health Innovation Active ETF
3.65%
Global X Aging Population ETF
3.31%
Acruence Active Hedge US Equity ETF
2.58%
First Trust Indxx Medical Devices ETF
2.23%
State Street SPDR S&P Health Care Equipment ETF
1.88%
JPMorgan Healthcare Leaders ETF
1.8%
PGIM Jennison Better Future ETF
1.78%
ROBO Global Healthcare Technology & Innovation ETF
1.73%
더 보기
iShares U.S. Medical Devices ETF
비율4.72%
Future Fund Long/Short ETF
비율3.86%
iShares Health Innovation Active ETF
비율3.65%
Global X Aging Population ETF
비율3.31%
Acruence Active Hedge US Equity ETF
비율2.58%
First Trust Indxx Medical Devices ETF
비율2.23%
State Street SPDR S&P Health Care Equipment ETF
비율1.88%
JPMorgan Healthcare Leaders ETF
비율1.8%
PGIM Jennison Better Future ETF
비율1.78%
ROBO Global Healthcare Technology & Innovation ETF
비율1.73%
주식 배당금
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
데이터 없음
주식 분할
날짜
배당락일
유형
비율
May 07, 2020
Split
1→3
날짜
배당락일
유형
비율
May 07, 2020
Split
1→3
